The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
Open accessAbstract
Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,405
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547 · cited 1×
“Moreover, the general inverse relationship between HDL levels and CHD is observed in the elderly (4), and was seen in this study (Fig.”
Molecular physiology of reverse cholesterol transport.
Fielding, C. J., & Fielding, P. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39898-9 · Cited by 1,448
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., & Clift, S. M. (1991) · Nature · doi:10.1038/353265a0 · Cited by 986
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Self-citationSerum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men
Rhoads, G. G., Gulbrandsen, C. L., & Kagan, A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602052940601 · Cited by 878
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Self-citationHigh-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
Parthasarathy, S., Barnett, J., & Fong, L. G. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90314-n · Cited by 827
Badimon, J. J., Badimon, L., & Fuster, V (1990) · Journal of Clinical Investigation · doi:10.1172/jci114558 · Cited by 764
Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., & Laks, H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115532 · Cited by 737
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Brown, M. L., Inazu, A., Hesler, C. B., Agellon, L. B., Mann, C., Whitlock, M. E., Marcel, Y. L., Milne, R. W., Koizumi, J., Mabuchi, H., et al. (1989) · Nature · doi:10.1038/342448a0 · Cited by 467
Self-citationTHE NHLBI TWIN STUDY OF CARDIOVASCULAR DISEASE RISK FACTORS: METHODOLOGY AND SUMMARY OF RESULTS
FEINLEIB, M., GARRISON, R. J., FABSITZ, R., CHRISTIAN, J. C., HRUBEC, Z., BORHANI, N. O., KANNEL, W. B., ROSENMAN, R., SCHWARTZ, J. T., & WAGNER, J. O. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112464 · Cited by 449
Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
Marotti, K. R., Castle, C. K., Boyle, T. P., Lin, A. H., Murray, R. W., & Melchior, G. W. (1993) · Nature · doi:10.1038/364073a0 · Cited by 445
Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.
Pászty, C., Maeda, N., Verstuyft, J., & Rubin, E. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117412 · Cited by 374
TEN-YEAR INCIDENCE OF CORONARY HEART DISEASE IN THE HONOLULU HEART PROGRAM
YANO, K., REED, D. M., & MCGEE, D. L. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113787 · Cited by 369
Self-citationAgellon, L. B., Walsh, A., Hayek, T., Moulin, P., Jiang, X. C., Shelanski, S. A., Breslow, J. L., & Tall, A. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99088-5 · Cited by 298
Self-citationApolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux.
Rothblat, G., Mahlberg, F., Johnson, W., & Phillips, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40761-8 · Cited by 266
Hayek, T., Masucci-Magoulas, L., Jiang, X., Walsh, A., Rubin, E., Breslow, J. L., & Tall, A. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118255 · Cited by 265
Self-citationInazu, A., Jiang, X. C., Haraki, T., Yagi, K., Kamon, N., Koizumi, J., Mabuchi, H., Takeda, R., Takata, K., & Moriyama, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117537 · Cited by 247
Worth, R. M., & Kagan, A. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90022-6 · Cited by 238
Reichl, D., & Miller, N. E. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.6.785 · Cited by 237
Dammerman, M., Sandkuijl, L. A., Halaas, J. L., Chung, W., & Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4562 · Cited by 227
Marcel, Y. L., McPherson, R., Hogue, M., Czarnecka, H., Zawadzki, Z., Weech, P. K., Whitlock, M. E., Tall, A. R., & Milne, R. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114397 · Cited by 215
Self-citationRISK FACTORS FOR CORONARY HEART DISEASE IN ADULT FEMALE TWINS
AUSTIN, M. A., KING, M.-C., BAWOL, R. D., HULLEY, S. B., & FRIEDMAN, G. D. (1987) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114531 · Cited by 207
Hirano, K.-I., Yamashita, S., Kuga, Y., Sakai, N., Nozaki, S., Kihara, S., Arai, T., Yanagi, K., Takami, S., Menju, M., et al. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.11.1849 · Cited by 178
Cohen, J. C., Wang, Z., Grundy, S. M., Stoesz, M. R., & Guerra, R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117603 · Cited by 162
Hayek, T., Azrolan, N., Verdery, R. B., Walsh, A., Chajek‐Shaul, T., Agellon, L. B., Tall, A. R., & Breslow, J. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116683 · Cited by 133
Self-citationTakahashi, K., Jiang, X., Sakai, N., Yamashita, S., Hirano, K., Bujo, H., Yamazaki, H., Kusunoki, J., Miura, T., & Kussie, P. H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116802 · Cited by 130
Transgenic mouse models of lipoprotein metabolism and atherosclerosis.
Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8314 · Cited by 124
Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I.
Khoo, J., Miller, E. R., McLoughlin, P., & Steinberg, D. H. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42832-9 · Cited by 104
Bu, X., Warden, C. H., Xia, Y.-R., Meester, C. D., Puppione, D. L., Teruya, S., Lokensgard, B., Daneshmand, S., Brown, J., Gray, R. J., et al. (1994) · Human Genetics · doi:10.1007/bf00201563 · Cited by 71
Ohta, T., Nakamura, R., Takata, K., Saito, Y., Yamashita, S., Horiuchi, S., & Matsuda, I. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40055-0 · Cited by 55
Cited by
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
von Eckardstein, A., Nofer, J.-R., & Assmann, G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.13 · Cited by 695
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 625
Metadata
- Authors
- Zhong, S., Sharp, D. S., Grove, J. S., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-06-15
- Volume
- 97
- Issue
- 12
- Pages
- 2917-2923
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2125757745
- Cited by
- 583
- References
- 41
- FWCI
- 31.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.